ROCHE RECEIVES FDA APPROVAL FOR THE FIRST COMPANION DIAGNOSTIC TO IDENTIFY PATIENTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER ELIGIBLE FOR TARGETED TREATMENT WITH VYLOY

Reuters · 10/18 18:13

Please log in to view news